EPI 003
Alternative Names: EPI-003Latest Information Update: 27 Nov 2024
Price :
$50 *
At a glance
- Originator Epigenic Therapeutics
- Class Antivirals; Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 19 Nov 2024 The Medicines and Medical Devices Safety Authority approves clinical trial application for EPI 003 in Hepatitis B in New Zealand
- 19 Nov 2024 Epigenic Therapeutics plans a phase I trial for Hepatitis B in Australia, China, New Zealand and Hong kong (IV) (NCT06661148)
- 05 Jun 2024 Preclinical trials in Hepatitis B in China (Parenteral) before June 2024